Document Type : Systematic Review
Author
Clinical Research Development Unit (FACRDU), Department of geriatrician, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
10.22034/mphrj.2026.612966.1138
Abstract
Background: Hypothyroidism is associated with a broad spectrum of neurocognitive manifestations, including impaired memory, reduced attention, slowed information processing, executive dysfunction, and alterations in mood. Although levothyroxine (LT4) is the standard treatment for hypothyroidism, normalization of thyroid-stimulating hormone (TSH) does not necessarily guarantee complete neurological or cognitive recovery. Persistent cognitive complaints among biochemically euthyroid patients have consequently stimulated interest in alternative thyroid hormone replacement strategies.
Objective: This systematic review examines the effects of different thyroid hormone replacement strategies on cognitive recovery in patients with hypothyroidism, emphasizing conventional LT4 monotherapy, combined LT4/liothyronine (LT3) therapy, and individualized treatment approaches.
Methods: Relevant clinical trials, observational studies, systematic reviews, and meta-analyses were considered. Cognitive outcomes included memory, attention, executive functioning, processing speed, and global cognitive performance. Evidence was evaluated according to study design, population characteristics, treatment duration, and neuropsychological assessment methods. The PRISMA 2020 framework informed the proposed reporting structure.
Results: Available evidence indicates that overt hypothyroidism is associated with measurable cognitive impairment and that thyroid hormone replacement can improve several clinical and neuropsychological manifestations. However, cognitive recovery varies considerably between individuals. Randomized trials have generally failed to demonstrate consistent cognitive superiority of combined LT4/LT3 treatment over LT4 monotherapy. A recent systematic review involving 85 studies reported a pooled prevalence of neurocognitive impairment of approximately 29% among hypothyroid populations, although this estimate does not represent treatment-induced recovery. Evidence concerning alternative replacement strategies remains heterogeneous, particularly regarding long-term cognitive outcomes.
Conclusion: Cognitive recovery should be considered an important therapeutic outcome beyond biochemical normalization. Current evidence supports LT4 as first-line treatment, while the potential cognitive benefits of individualized combination therapy require further investigation through adequately powered randomized trials.
Keywords
Subjects